Amber B. Jones

555 total citations
9 papers, 250 citations indexed

About

Amber B. Jones is a scholar working on Molecular Biology, Genetics and Oncology. According to data from OpenAlex, Amber B. Jones has authored 9 papers receiving a total of 250 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 4 papers in Genetics and 4 papers in Oncology. Recurrent topics in Amber B. Jones's work include Cancer, Hypoxia, and Metabolism (4 papers), Glioma Diagnosis and Treatment (4 papers) and CAR-T cell therapy research (3 papers). Amber B. Jones is often cited by papers focused on Cancer, Hypoxia, and Metabolism (4 papers), Glioma Diagnosis and Treatment (4 papers) and CAR-T cell therapy research (3 papers). Amber B. Jones collaborates with scholars based in United States and Japan. Amber B. Jones's co-authors include Anita B. Hjelmeland, Gregory K. Friedman, Anh Tran, Nathaniel Boyd, Joshua D. Bernstock, G. Yancey Gillespie, Lawrence S. Lamb, Emily R. Gordon, Sara J. Cooper and David K. Crossman and has published in prestigious journals such as Pharmacological Reviews, Theranostics and Cells.

In The Last Decade

Amber B. Jones

9 papers receiving 248 citations

Peers

Amber B. Jones

MB

CR

IMMUN

GENET

ONCOL

Jennifer P. Newman Singapore

Amanda L. Rinkenbaugh United States

Shixue Yang China

Biao Hong China

Xiangguo Xia China

Pavlina Chuntova United States

Cécile Henry France

Alice Boissard France

Zhitao Zong China

Angana Biswas India

Jennifer P. Newman Singapore

Amber B. Jones

139 ×1.0

MB

74 ×0.8

CR

62 ×0.9

IMMUN

100 ×1.6

GENET

121 ×2.0

ONCOL

Citations per year, relative to Amber B. Jones Amber B. Jones (= 1×) peers Jennifer P. Newman

Countries citing papers authored by Amber B. Jones

Since Specialization

Citations

This map shows the geographic impact of Amber B. Jones's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amber B. Jones with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amber B. Jones more than expected).

Fields of papers citing papers by Amber B. Jones

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amber B. Jones. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amber B. Jones. The network helps show where Amber B. Jones may publish in the future.

Co-authorship network of co-authors of Amber B. Jones

This figure shows the co-authorship network connecting the top 25 collaborators of Amber B. Jones. A scholar is included among the top collaborators of Amber B. Jones based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amber B. Jones. Amber B. Jones is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Jones, Amber B., Sam E. Gary, Elizabeth A. Beierle, et al.. (2024). Temozolomide and the PARP Inhibitor Niraparib Enhance Expression of Natural Killer Group 2D Ligand ULBP1 and Gamma-Delta T Cell Cytotoxicity in Glioblastoma. Cancers. 16(16). 2852–2852. 6 indexed citations

2.

Jones, Amber B., et al.. (2024). Therapeutic advantage of combinatorial chimeric antigen receptor T cell and chemotherapies. Pharmacological Reviews. 77(1). 100011–100011. 3 indexed citations

3.

Jones, Amber B., Corinne E. Griguer, Braden C. McFarland, et al.. (2023). Tumor Treating Fields Alter the Kinomic Landscape in Glioblastoma Revealing Therapeutic Vulnerabilities. Cells. 12(17). 2171–2171. 2 indexed citations

4.

Jones, Amber B., Emily R. Gordon, Christopher D. Willey, et al.. (2023). Carmofur prevents cell cycle progression by reducing E2F8 transcription in temozolomide-resistant glioblastoma cells. Cell Death Discovery. 9(1). 451–451. 6 indexed citations

5.

Jones, Amber B., Emily R. Gordon, David K. Crossman, et al.. (2022). Targeting Acid Ceramidase Inhibits Glioblastoma Cell Migration through Decreased AKT Signaling. Cells. 11(12). 1873–1873. 13 indexed citations

6.

Jones, Amber B., et al.. (2022). Regulation of NKG2D Stress Ligands and Its Relevance in Cancer Progression. Cancers. 14(9). 2339–2339. 36 indexed citations

7.

Jones, Amber B., Emily R. Gordon, Jeremy C. Allegood, et al.. (2021). DDRE-06. TARGETING THE SPHINGOLIPID BALANCE VIA ACID CERAMIDASE INHIBITION TO DECREASE GROWTH OF TMZ-RESISTANT GLIOBLASTOMA AND BLOCK MIGRATION. Neuro-Oncology. 23(Supplement_6). vi75–vi75. 1 indexed citations

8.

Benavides, Gloria A., Sixue Zhang, Anh Tran, et al.. (2021). A role for GLUT3 in glioblastoma cell invasion that is not recapitulated by GLUT1. Cell Adhesion & Migration. 15(1). 101–115. 30 indexed citations

9.

Boyd, Nathaniel, Anh Tran, Joshua D. Bernstock, et al.. (2020). Glioma stem cells and their roles within the hypoxic tumor microenvironment. Theranostics. 11(2). 665–683. 153 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact